Biowatch

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE." Derived from the opening of its international nonproprietary...
Sales Rise 11%, but Chong Kun Dang’s Q2 Operating Profit Slips 10%

Sales Rise 11%, but Chong Kun Dang’s Q2 Operating Profit Slips 10%

Chong Kun Dang posted higher sales in the second quarter of this year, but its operating profit fell 10% from a year earlier.
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s botulinum toxin product Nabota has entered Kuwait, expanding its Middle East footprint to...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
South Korea Overhauls Pharma and Biotech Disclosure Rules Following Samchundang Controversy

South Korea Overhauls Pharma and Biotech Disclosure Rules Following Samchundang Controversy

South Korean financial authorities are overhauling disclosure regulations across the pharmaceutical and biotechnology...
Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%

Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%

Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major...
Ilyang Pharmaceutical Commits 17.6 Billion Won to China Comeback with Flagship Wonbi-D

Ilyang Pharmaceutical Commits 17.6 Billion Won to China Comeback with Flagship Wonbi-D

Ilyang Pharmaceutical is mounting a fresh push into the Chinese market, reviving a business operation that had been...
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...